Newsletter
Every new paper in this field, in your inbox.
A retrospective cohort study analyzed 29 patients with peritoneal sarcomatosis who underwent cytoreductive surgery (CRS) with bidirectional intraoperative chemotherapy (BDIC) using intravenous ifosfamide and hyperthermic intraperitoneal chemotherapy (HIPEC). The overall survival rates at 6, 12, 24, and 48 months after CRS/BDIC were 93.1%, 89.2%, 81.4%,…
An international consensus has been reached on the definition of textbook oncologic outcomes (TOO) in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastasis. The TOO parameters for CRS/HIPEC in this context include absence of certain complications, achievement of complete cytoreduction, and…
Among patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for nongynecologic cancers, intra- and interpatient drug response heterogeneity was observed. Researchers generated patient-derived tumor organoids (PDTOs) and conducted in vitro drug screens to assess drug response. PDTOs were successfully generated from 13 out of…
The study aimed to identify predictive factors for early recurrence and survival outcomes in colorectal cancer patients with liver and peritoneal metastases who underwent combined liver resection, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy. The results showed that patients with advanced primary tumors (PT4 and/or PN2…
The study aimed to identify predictive factors for early recurrence and survival outcomes in colorectal cancer patients with liver and peritoneal metastases who underwent combined liver resection, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy. The results showed that patients with advanced primary tumors (PT4 and/or PN2…
Expert consensus was achieved on the definition of textbook oncologic outcomes (TOO) in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastasis. The consensus criteria included the absence of unplanned re-operations, severe postoperative complications, unplanned readmissions, 90-day postoperative mortality, and contraindications for…
The clinical effectiveness of preoperative 18F-FDG PET/CT in predicting pathological tumor grade in patients with pseudomyxoma peritonei (PMP) originating from the appendix was evaluated in this retrospective cohort study. The study found that high-grade PMP patients had a significantly higher median standardized uptake value (SUVmax)…
This study investigated the impact of the extent of surgery on late adverse effects (LAEs) in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The study found that patients undergoing extensive CRS experienced persistent impaired gastrointestinal function in terms of diarrhea, compared to…
Researchers conducted a retrospective cohort study on 163 patients who underwent cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) between 2016 and 2022. They found that 31.9% of patients were at risk of financial toxicity, with higher out-of-pocket expenditures and lower income quartiles being significant risk…
Actual 5-year survival rates after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for patients with peritoneal carcinomatosis (PC) of colorectal origin were reported in this study. A total of 103 patients were analyzed, with a median follow-up of survivors at 88 months. The 5-year overall…
